Human CD17 / Lactosylceramide

Mouse

Human (tested or 100% immunogen sequence identity)

IgM Monoclonal

HO18.3G-6.F5

Unconjugated

PEG purified

Azide-free, BSA-free. Also available Unmodified.

Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

Human CD17 / Lactosylceramide

• Immunofluorescence (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

The applications listed have been tested for the unmodified form of this product. Other forms have not been tested. CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. TNFa-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization. Optimal dilution of the CDw17 antibody should be determined by the researcher.

1X PBS

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.